Literature DB >> 16632646

Modification and uptake of a cisplatin carbonato complex by Jurkat cells.

Corey R Centerwall1, Kirk A Tacka, Deborah J Kerwood, Jerry Goodisman, Bonnie B Toms, Ronald L Dubowy, James C Dabrowiak.   

Abstract

The interactions of Jurkat cells with cisplatin, cis-[Pt(15NH3)2Cl2]1, are studied using 1H-15N heteronuclear single quantum coherence (HSQC) NMR and inductively coupled plasma mass spectrometry. We show that Jurkat cells in culture rapidly modify the monocarbonato complex cis-[Pt(15NH3)2(CO3)Cl]- (4), a cisplatin species that forms in culture media and probably also in blood. Analysis of the HSQC NMR peak intensity for 4 in the presence of different numbers of Jurkat cells reveals that each cell is capable of modifying 0.0028 pmol of 4 within approximately 0.6 h. The amounts of platinum taken up by the cell, weakly bound to the cell surface, remaining in the culture medium, and bound to genomic DNA were measured as functions of time of exposure to different concentrations of drug. The results show that most of the 4 that has been modified by the cells remains in the culture medium as a substance of molecular mass <3 kDa, which is HSQC NMR silent, and is not taken up by the cell. These results are consistent with a hitherto undocumented extracellular detoxification mechanism in which the cells rapidly modify 4, which is present in the culture medium, so it cannot bind to the cell. Because there is only a slow decrease in the amount of unmodified 4 remaining in the culture medium after 1 h, -1.1 +/- 0.4 microM h(-1), the cells subsequently lose their ability to modify 4. These observations have important implications for the mechanism of action of cisplatin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632646     DOI: 10.1124/mol.106.023184

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Effects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.

Authors:  Brad T Benedetti; Erica J Peterson; Peyman Kabolizadeh; Alberto Martínez; Ralph Kipping; Nicholas P Farrell
Journal:  Mol Pharm       Date:  2011-05-16       Impact factor: 4.939

2.  Determination of the kinetic profile of a dinuclear platinum anticancer complex in the presence of sulfate: introducing a new tool for the expedited analysis of 2D [(1)H,( 15)N] HSQC NMR spectra.

Authors:  Rasha A Ruhayel; Ben Corry; Carlos Braun; Donald S Thomas; Susan J Berners-Price; Nicholas P Farrell
Journal:  Inorg Chem       Date:  2010-11-10       Impact factor: 5.165

3.  Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.

Authors:  Rathindra N Bose; Leila Maurmann; Robert J Mishur; Linda Yasui; Shefalika Gupta; W Scott Grayburn; Heike Hofstetter; Tara Salley; Tara Milton
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

4.  Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.

Authors:  Brittany F Karas; Jordan M Hotz; Brian T Buckley; Keith R Cooper
Journal:  Aquat Toxicol       Date:  2020-10-13       Impact factor: 5.202

Review 5.  Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.

Authors:  Katarzyna Gałczyńska; Zuzanna Drulis-Kawa; Michał Arabski
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.